Volltext verfügbar nach Anmeldung bzw. im Campus-Netz.
Comprehensive Positive Phase 3 Data for Alexion’s ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria Presented at American Society of Hematology (ASH) Annual Meeting and Published in Blood
In: Business Wire (English), 2018-12-03
Online
Zeitungsartikel
Zugriff:
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the presentation of comprehensive positive Phase 3 data for ALXN1210, the company’s investigational long-acting C5 complement inhibitor, at the American Society of Hematology (ASH) Annual Meeting, taking place December 1-4, 2018. The presentations included both previously announced and new data from the two large Phase 3 studies in patients with paroxysmal nocturnal hemoglobinuria (PNH) who had either never been treated with a complement inhibitor before or who had been stable on Soliris® treatment. The conference presentations coincided with publications in Blood of the positive results on all primary and key secondary endpoints from these two studies. [ABSTRACT FROM PUBLISHER]
Titel: |
Comprehensive Positive Phase 3 Data for Alexion’s ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria Presented at American Society of Hematology (ASH) Annual Meeting and Published in Blood
|
---|---|
Autor/in / Beteiligte Person: | Alexion Pharmaceuticals, Inc. |
Zeitschrift: | Business Wire (English), 2018-12-03 |
Veröffentlichung: | 2018 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|